{"id":"W2981745131","doi":"","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"PMC","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Oncology; Germ cell tumors; Open label study; Mesothelioma; Phases of clinical research; Antibody; Toxicity; Chemotherapy; Lymphoma; Immunology; Pathology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001003385,0.001191552,0.001611441,0.000272859,0.0004123313,0.0009611126,0.0004794281,0.000953707,0.002351323],"category_scores_gemma":[0.0006550614,0.0004652099,0.001009471,0.0002539682,0.0007541372,0.001000728,0.0002493609,0.002694786,0.0006237936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007084696,"about_ca_system_score_gemma":0.001013748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008390833,"about_ca_topic_score_gemma":0.002146643,"domain_scores_codex":[0.9997142,0.0001183828,0.00001055169,0.00005596593,0.0000237115,0.00007710382],"domain_scores_gemma":[0.9995465,0.0001050232,0.00005081266,0.00003710435,0.00002345106,0.0002371979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7313683,0.06011044,0.01038465,0.0008259151,0.001504927,0.0006645787,0.0004424522,0.003928862,0.05788701,0.0005340753,0.005082764,0.1272661],"study_design_scores_gemma":[0.6051047,0.3679457,0.01632442,0.00003540085,0.0004328678,0.0005937091,0.000133378,0.002405965,0.002733136,0.0003876747,0.003861731,0.00004115938],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994124,0.001893521,0.0005939667,0.0004140231,0.0001264513,0.001023657,0.0006729321,0.00005811228,0.001093397],"genre_scores_gemma":[0.9931394,0.001293838,0.001229741,0.0006787797,0.0001171526,0.0009222226,0.001244327,0.00002092024,0.00135353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002351323,"threshold_uncertainty_score":0.007865906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03523732062145055,"score_gpt":0.3729277082655465,"score_spread":0.3376903876440959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}